Tiens Biotech Group Usa Inc - Amended Current report filing (8-K/A)
13 Maggio 2008 - 11:28PM
Edgar (US Regulatory)
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 1)
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): March 13, 2008
TIENS
BIOTECH GROUP (USA), INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-32477
|
|
75-2926439
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
|
|
Identification
Number)
|
No.
6,
Yuanquan Road, Wuqing New-Tech Industrial Park, Tianjin, China
301700
(Address
of principal executive offices)
Registrant's
telephone number, including area code:
(86)
22-8213-7658
Not
applicable
(Former
name or former address, if changed since last report.)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2.):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
Soliciting
materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
2.01. Completion of Acquisition or Disposition of
Assets.
As
previously reported under Item 2.01 of the Current Report on Form 8-K filed
by
Tiens Biotech Group (USA), Inc. (the “Company”) with the Securities and Exchange
Commission on March 20, 2008, the Company’s subsidiary, Tianshi International
Holdings Group Limited (“Tianshi International”), and the Company’s 80% owned
subsidiary, Tianjin Tianshi Biological Development Co., Ltd. (“Biological”),
closed the acquisition by Tianshi International of all of the registered share
capital of Tianjin Tiens Life Resources Co., Ltd. (“Life Resources”) pursuant to
a Sale and Purchase Agreement, dated December 20, 2007, by and among Tianshi
International, Biological, Tianshi International Investment Group Co., Ltd.
and
Tianjin Tianshi Biological Engineering Co., Ltd. The description of the
acquisition included in the March 20, 2008 Form 8-K is incorporated by reference
herein.
This
Current Report on Form 8-K/A provides the historical financial statements of
the
business acquired under Item 9.01(a) and the pro forma financial information
under Item 9.01(b), which financial statements and information were not included
in the March 20, 2008 Form 8-K.
Item
9.01. Financial Statements and Exhibits.
(a)
Financial Statements of Businesses Acquired.
Audited
Financial statements for Life Resources as of and for the years ended December
31, 2007 and 2006 are filed as Exhibit 99.1 to this amendment and incorporated
herein by reference.
(b)
Pro
Forma Financial Information.
The
pro
forma financial information with respect to the transaction described in Item
2.01 is field as Exhibit 99.2 to this amendment and incorporated herein by
reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
TIENS
BIOTECH GROUP (USA), INC.
|
|
|
|
Date:
May 13, 2008
|
By:
|
/s/
Wenjun Jiao
|
|
|
Name:
Wenjun Jiao
|
|
|
Title:
Chief Financial Officer
|
Exhibits
.
Exhibit Number
|
|
Description
|
|
|
|
99.1
|
|
Financial
statements of business acquired.
|
|
|
|
99.2
|
|
Unaudited
pro forma financial information.
|
Grafico Azioni Tiens Biotech GR Usa (AMEX:TBV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Tiens Biotech GR Usa (AMEX:TBV)
Storico
Da Giu 2023 a Giu 2024